A Report on a 7-year Follow up of the Surgical Management with PRGF®- ENDORET® of Oncologic Patients Affected by Intravenous Bisphosphonate Related Osteonecrosis of the Jaw

Abstract

Mozzati et al., Surgery 2013, S12 http://dx.doi.org/10.4172/2161-1076.S12-011 Research ArticleOpen Access AbstractBRONJ is an important complication in bisphosphonate therapy that dramatically influences the patient's quality of life and requires immediate intervention. The situation is worsened by the fact that its management is still an open issue, with no definitive standard of care. The aim of this paper is to present the short, middle and long term (7 years) results of surgical treatment of 32 BRONJ cases involving the use of PRGFNo intraoperative complications were observed; the short period freedom from light complications was 84.4%, with complete remittal in a few weeks; after 7 years the freedom from complications and need of re intervention is 100%. The freedom from onset of a new BRONJ on untreated sites was 100% up to 4 years after which decreased to 82%. The surgical procedure with the applications of platelet-enriched preparations can thus be considered favorably tested, having led to rapid osseous remodeling and to a satisfactory closure of the mucosa thus shielding the area from infection and reducing symptomatology.

PRGF exerts a cytoprotective role in zoledronic acid-treated oral cells

“…ZA+PRGF: treatment with zoledronic acid + PRGF). *Statistically significant differences compared to the control and ZA+PRGF treatments (p < 0.05) BRONJ has been reported, thus improving wound healing, enhancing vascularization and osseous and epithelial tissues regeneration [11,12,40,41]. The in vitro findings obtained in this study may be behind of these good clinical data.…”

Stage-specific therapeutic strategies of medication-related osteonecrosis of the jaws: a systematic review and meta-analysis of the drug suspension protocol

“…This led to a final selection of 13 studies [42][43][44][45][46][47][48][49][50][51][52][53][54]. Among these, three studies had parts which had to be excluded as they did not meet inclusion criteria or met the exclusion criteria: one [43] had a part which treated unconventional therapies; one [50] had a part in which outcomes were not evaluated according to stage at diagnosis; one [51] had a part in which treatment outcome was evaluated on…”

“…Nine studies had a retrospective design [42-46, 48, 50, 53, 54] and four were prospective studies [47,49,51,52]; one was single-blinded [45], whereas for the other 12, these data were not available. Five studies were conducted in private practice [46,50,51,53,54], whereas five studies were performed in a university setting [43,44,[47][48][49]. Only one study was conducted both in private practice and in university [45].…”

Dental Implant Placement in Patients on Bisphosphonate Therapy: a Systematic Review

“…Even better improvement outcomes were seen with PRF (platelet-rich fibrin) with studies carried out by Dincă et al [ 49 ] and Kim et al [ 50 ] with significantly better recovery and less delayed healing signs. Studies carried out by Mozzati [ 51 , 52 ] showed that treatment with PRGF (plasma rich in growth factors) showed the best after-effects with no complications or recurrences during the follow-up. Preventive and diagnostic strategies are important in avoiding implant-related BRONJ, according to Marx et al [ 53 ] and Kunchur et al [ 54 ], CTX values of 150 pg/mL and more greatly reduced the risk of osteonecrosis occurrence.…”